Clinical Spectrum of Stiff Person Syndrome: A Review of Recent Reports by Sarva, Harini et al.
Reviews







& William L. Severt
3
1Department of Neurology, Maimonides Medical Center, Brooklyn, NY, USA, 2 Parkinson Disease and Movement Disorders Center, Department of Neurology,
University of Pennsylvania, PA, USA, 3Department of Neurology, Division of Movement Disorders, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel
Medical Center, New York, NY, USA
Abstract
Background: ‘‘Classic’’ stiff person syndrome (SPS) features stiffness, anti-glutamic acid decarboxylase (anti-GAD) antibodies, and other findings. Anti-GAD
antibodies are also detected in some neurological syndromes (such as ataxia) in which stiffness is inconsistently present. Patients with otherwise ‘‘classic’’ SPS may
either lack anti-GAD antibodies or be seropositive for others. Hence, SPS cases appear to fall within a clinical spectrum that includes conditions such as progressive
encephalomyelitis with rigidity and myoclonus (PERM), which exhibits brainstem and autonomic features. We have compiled herein SPS-spectrum cases reported
since 2010, and have segregated them on the basis of likely disease mechanism (autoimmune, paraneoplastic, or cryptogenic) for analysis.
Methods: The phrases ‘‘stiff person syndrome’’, ‘‘PERM’’, ‘‘anti-GAD antibody syndrome’’, and ‘‘glycine receptor antibody neurological disorders’’ were
searched for in PubMed in January 2015. The results were narrowed to 72 citations after excluding non-English and duplicate reports. Clinical descriptions,
laboratory data, management, and outcomes were categorized, tabulated, and analyzed.
Results: Sixty-nine autoimmune, 19 paraneoplastic, and 13 cryptogenic SPS-spectrum cases were identified. SPS was the predominant diagnosis among the
groups. Roughly two-thirds of autoimmune and paraneoplastic cases were female. Anti-GAD antibodies were most frequently identified, followed by anti-
amphiphysin among paraneoplastic cases and by anti-glycine receptor antibodies among autoimmune cases. Benzodiazepines were the most commonly used
medications. Prognosis seemed best for cryptogenic cases; malignancy worsened that of paraneoplastic cases.
Discussion: Grouping SPS-spectrum cases by pathophysiology provided insights into work-up, treatment, and prognosis. Ample phenotypic and serologic
variations are present within the categories. Ruling out malignancy and autoimmunity is appropriate for suspected SPS-spectrum cases.
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Introduction
‘‘Stiff man’’ syndrome was first described in 1956 by Moersch and
Woltman.1,2 Along with observations from 13 other cases, they
described a 49-year-old man with progressive stiffness in his neck,
shoulders, and upper back, episodic painful muscle spasms, and
difficulty walking. Multiple similar case descriptions have since
followed. The term ‘‘stiff man’’ was recently replaced by the gender-
neutral ‘‘stiff person syndrome’’ (SPS), which gained significant
traction after Blum and Jankovic3 reported that approximately 20 of
the 84 reported cases between 1967 and 1991 were female. It was
Asher,4 however, in 1958, who first proposed this terminology.
The suspicion for an immunologic cause was raised by the
observations of frequent comorbid diabetes (up to 35% in some
series5) and other concomitant autoimmune diseases (vitiligo, celiac
sprue, rheumatologic diseases, and thyrogastric disorders)2,5,6 in
patients with SPS. Glutamic acid decarboxylase (GAD) antibodies
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(which in this manuscript will be referred to as anti-GAD antibodies,
a non-specific term that includes both anti-GAD antibody isoforms, as
described below) were first documented in association with SPS in
1988.7,8 Anti-GAD antibodies inhibited GAD activity and the
synthesis of gamma-aminobutyric acid (GABA) in vitro.2
GAD is a pyridoxal 59-phosphate-dependent enzyme and the rate-
limiting step in the synthesis of GABA. GAD is not only found in the
brain and pancreatic B-cells, but also in lower amounts in the liver,
kidneys, adrenal glands, ovaries, and testes.9 There are two GAD
isoforms, 65 and 67, which differ in their molecular weight, location,
and enzyme activity. Within the central nervous system, GAD65
localizes to the synaptic vesicles and its activity increases in response to
surging demands for GABA.2 GAD67 localizes to the cytoplasm and
generates a steady basal GABA level.2 Anti-GAD antibodies are
specific for either isoform: antibodies against GAD65 were reported in
about 80% of SPS cases (at times, the terms anti-GAD and anti-
GAD65 antibodies are used interchangeably in the literature), whereas
anti-GAD67 antibodies were reported in about 60%, with co-existence
presumed likely.2,6,10
An immune pathogenesis is accepted as the cause of SPS, but it
remains unclear whether anti-GAD antibodies are directly pathogenic
in vivo, unlike in diabetes.2 There are different possible explanations for
this. Whereas serum anti-GAD antibody titers in SPS are high enough
to produce endocrine damage, diabetics have lower serum titers that
are likely insufficient to cross the blood–brain barrier and lead to
central nervous system (CNS) damage.2 Extremely high titers of anti-
GAD antibodies in SPS can trigger multi-antigen autoimmunity and
the development of other concomitant autoimmune diseases, such as
thyroid disease, but not necessarily vice versa.9 Besides a difference in
titers, in SPS both the linear and the conformational epitopes are
recognized by anti-GAD65 antibodies, while in diabetes only the
conformational epitopes are recognized, triggering a specific patho-
genic mechanism.2 Other arguments against a pathogenic role for these
antibodies include the lack of correlation between disease severity and
intrathecal synthesis and lack of evidence of T-cell-mediated damage of
central GABAergic neurons.5,10 In addition, antibody titers in SPS do
not appear to vary with clinical response to treatment. Monitoring
antibody titers during the course of treatment is, hence, unnecessary.5,11
Identification of the anti-GAD antibodies allowed the revision of the
diagnostic criteria for SPS, which were first proposed in 1967 by
Gordon et al.12 In 2009 Dalakas5 proposed two fundamental clinical
symptoms, truncal and proximal limb stiffness, stemming from co-
contraction of agonist and antagonist muscles and leading to
hyperlordosis, and superimposed episodic spasms. According to
Dalakas, the presence of all of the following are required for a
diagnosis of SPS: 1) stiffness of the axial muscles, particularly in the
abdomen and thoracolumbar paraspinals, leading to hyperlordosis;
2) superimposed painful spasms triggered by tactile or auditory stimuli;
3) electromyographic evidence of continuous motor unit activity in
agonist and antagonist muscles; 4) absence of other neurological
findings that may suggest an alternative diagnosis; and 5) positive
serology confirmed by immunocytochemistry, Western blot, or radio-
immunoassay.
Although these criteria best define the ‘‘classic’’ SPS phenotype, it is
now clear that some patients have positive anti-GAD antibodies and
stiffness that is confined to a limb (typically a leg, in what has been
called stiff-limb syndrome, SLS).13 Eventual spread of stiffness to the
trunk was described.13 SLS is likely due to local interneuronitis, in
which there is selective destruction of spinal interneurons in the gray
matter.13 Interestingly, long-tract damage was not noted in these cases.
The associated reflexive spasms likely result from an excessive response
to descending reticulospinal activity at the segmental level, as shown
electrophysiologically by hypersynchronous segmented discharges.13
The exact cause of the interneuronitis is unknown but may be due to
similar mechanisms that occur in the presence of intrinsic spinal cord
tumors or vascular insufficiency.13 These patients may develop urinary
and transient brainstem symptoms (about 50%), have seropositivity to
anti-GAD antibodies in about 15% of cases, and have a limited
response to GABAergic treatments.13,14 In fact, patients with stiff limb
syndrome were reported likely to be wheelchair bound after a mean of
3.5 years.13 Some authors also advocate for the existence of a distinct
stiff-trunk syndrome,14 and a jerking-man syndrome with generalized
myoclonus.13,15 The development of highly sensitive antibody
detection assays also allowed the identification of anti-GAD antibodies
in neurologic conditions where rigidity may be absent. Phenotypes
include cerebellar ataxia, epilepsy, and cognitive impairment.2 All of
the above suggest the existence of a spectrum of SPS expanding well
beyond the ‘‘classic’’ phenotype.
Patients within this SPS spectrum have antibodies against other
proteins of the GABAergic synapse, including amphiphysin and
gephyrin, which may be identified in isolation.10,16 Amphiphysin is a
cytosolic pre-synaptic vesicle protein. Anti-amphiphysin antibodies are
often associated with malignancy, and phenotypically these cases may
differ from anti-GAD65 positive SPS with more prominent neck and
arm stiffness.17 In addition, these antibodies were also detected in
neurologic conditions such as encephalopathy, myelopathy, and
neuronopathy.17 Gephyrin interacts with the GABA receptor-asso-
ciated protein (GABARAP) in the assembly of the GABA-A
receptor.10,16 Interestingly, about 70% of patients with anti-GAD65
seropositivity may also have antibodies against GABARAP.10,16
Antiglycine receptors (anti-GlyR antibodies) are present in some
SPS-spectrum cases, and are the hallmark of progressive encephalo-
myelitis with rigidity and myoclonus (PERM). In this condition there is
prominent brainstem, autonomic, and spinal cord involvement.
Concurrent anti-GAD antibodies can also be found.18 In a study of
45 prospective and 56 retrospective cases of PERM, approximately 33
of the former and 10 of the latter were positive for anti-GAD
antibodies.18 Histology from available specimens demonstrated
inflammatory and microglial changes and cell loss in the pons,
medulla, cerebellum, spinal cord, and autonomic ganglia.13 Patients
with PERM had increased T2 fluid-attenuated inversion recovery
signal of spinal cord and brainstem on magnetic resonance imaging
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(MRI).18 Despite its severity, the response to immunomodulatory
therapies, including methylprednisolone, can be robust.13,18
Glycine receptors belong to a family of ligand-gated ion channels
composed of two alpha- and three beta-subunits. Activation of these
receptors leads to chloride influx, membrane hyperpolarization, and
reduction in neuronal excitation. There are three types of glycine
receptors: alpha 1, 2, and 3. The first type localizes to the brainstem,
thalamus, hypothalamus, superior colliculus, and spinal cord. The
distribution of the others remains incompletely defined.18
Other antibodies were found in patients within the spectrum of SPS.
In a study examining the antibody profile of 13 patients with SPS,
eight were found to have non-organ-specific antibodies, including
antibodies to nuclear, smooth muscle, and mitochondrial antigens, six
had thyrogastric antibodies, five had islet-cell antibodies, and four had
anti-GAD antibodies.9
Given the considerable phenotypical variability found in patients
with anti-GAD antibodies, the presence of different auto-antibodies
associated with similar phenotypes, and seronegative patients fulfilling
almost all of Dalakas’ criteria for ‘‘classic’’ SPS, classifying patients
within the SPS spectrum-based on their phenomenology can be, in our
opinion, impractical and ambiguous. Instead, we argue that a
classification based on likely etiology offers the most useful guidance
in terms of prognosis and treatment response. Under this framework,
cases within the SPS spectrum can be segregated into one of three
mutually exclusive groups:9,19,20 1) autoimmune cases, defined by
autoantibody positivity (in serum and/or cerebrospinal fluid [CSF]) in
the absence of an underlying malignancy; 2) paraneoplastic cases,
encompassing all cases emerging in the context of cancer; and
3) cryptogenic cases, that is, all seronegative cases in which an
immunologic cause cannot be identified. All cases with malignancy
were labeled as paraneoplastic, as the original reports described a
mostly positive clinical response to anti-cancer treatments. If the cancer
therapy did not produce a response in the SPS-spectrum disorders, the
malignancy would more likely be a comorbidity rather than a likely
cause. This breakdown is purely an operational classification based on
the published papers’ reported diagnosis. It was difficult for us to
determine if each case met Dalakas’ criteria in their entirety, as
phenotypic descriptions were incomplete in a number of the reports,
despite the reported diagnoses. To better understand the character-
istics, disease behavior, and treatment response of SPS-spectrum cases
within each of these groups, we here review cases and case series of SPS
and related disorders published between 2010 and early 2015.
Methods
In January 2015, we searched PubMed for the phrases ‘‘stiff person
syndrome’’, ‘‘PERM’’, ‘‘anti-GAD antibody syndrome’’ and ‘‘glycine
receptor antibody neurological disorders’’. Of note, searching for ‘‘stiff
man syndrome’’ yielded the same results as searching for ‘‘stiff person
syndrome.’’ The resulting initial 706 citations were narrowed to 72 after
excluding non-English papers, duplicate reports, and papers published
before 2010. Papers with no available clinical information and reviews
without individual clinical descriptions were also excluded. January 2010
was selected as a cut-off for inclusion in an attempt to guarantee that most
of the published cases were using similar criteria to diagnose SPS-
spectrum cases, but also to adhere to the journal’s manuscript guidelines.
Clinical descriptions, laboratory data, treatment strategies, and outcomes,
when available, were extracted and tabulated into a MicrosoftH Excel
2010 spreadsheet. Three separate spreadsheets were created, one for each
subgroup (autoimmune, paraneoplastic, or cyptogenic), and cases were
segregated into one of these categories according to the definitions
mentioned above. Case series were treated as groups of case reports, and
each of the cases within the series was classified independently into one of
the tables. One case series21 presented consolidated data for all of its cases
and is presented here in a separate table (see Table 4) that includes
autoimmune, paraneoplastic, and cryptogenic subtypes. Attempting to
subdivide these cases into the prior three subgroups was thus not readily
possible due to lack of individual data.
Pertinent positives and pertinent negatives for symptoms, examina-
tion findings, laboratory data, treatment strategies, and outcomes were
coded in the tables as present (+) or absent (–), respectively. Fields were
left blank when the paper did not comment on a specific datum. Once
all data were entered, findings were summated within each category
and percentages of prevalence were calculated. Either medians or
means were calculated for all numeric data (i.e. age), depending on the
sample size. The prevalence numbers for the subdivisions are based on
the published diagnoses of SPS and its variants in the original reports.
Results
Data extracted from each of the SPS-spectrum subgroups are
presented in the following subsections.
Autoimmune SPS spectrum cases (Tables 1 and 2)
Sixty-nine cases of autoimmune SPS-spectrum disorders were
identified (Table 1), 46 (66.7%) of whom were female. Sex and age
at presentation were available in all but four cases: two were female,
but their age was not reported. Neither sex nor age was reported for
the other two. Ages at presentation ranged from 1 to 78 years, the
mean being 44 years. The median age at presentation in males was
45 years, whereas the mean age was 44.5 years in females.
In terms of their phenotypes, 48 cases (69.6%) received a diagnosis
of SPS. Of these, three had concomitant ataxia, two had orthostatic
tremor, two had corticobasal syndrome, one initially had stiff limb
syndrome, one had epilepsy, and one had anorexia. Nine (13%) had
findings consistent with PERM. Four (5.8%) received a diagnosis of
SLS, and another four had ataxia alone. Two (2.9%) had only
epilepsy, one of whom with behavioral changes. Finally, only one
(1.4%) of the autoimmune cases had clinical signs of schizophrenia,22
while another had isolated stiff trunk syndrome.14
Data on the time patients had symptoms before presentation were
available for 48. It ranged from less than 1 month to about 46 years, with
an average of 63.8 months (over 5 years). Forty-one (59.4%) described
cramps or spasms, 45 (65.2%) had limb stiffness, 29 (42%) had difficulty
walking, and 23 (33.3%) had pain. Sixteen (23.2%) had documented
concomitant autoimmunity besides diabetes (only two had documented
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absence of concomitant autoimmunity; data were lacking for the rest), and
26 (37.7%) had documented diabetes. In descending order of frequency,
other associated autoimmune conditions included five with isolated thyroid
disease; four with isolated vitiligo; three with isolated pernicious anemia;
one with coexisting thyroid disease and vitiligo; one with coexisting
pernicious anemia and vitiligo; one with coexisting myasthenia gravis and
pernicious anemia; and one with Graves’ disease. Eight (11.6% of all
autoimmune cases) had coexisting diabetes along with another auto-
immune disease.
Serum anti-GAD antibody testing was documented for 66/69
(95.6%), 58/66 (87.9%) being seropositive. Twenty-five of the 26
patients (96.2%) with diabetes were seropositive for anti-GAD
antibodies. Serum anti-GlyR antibody testing was documented for
17/69 (24.6%), and 11/69 (15.9%) were positive. Eight of these 11 had
PERM. Testing for other antibodies was documented in 26/69
(37.7%), and seven were positive for the following antibodies: three for
anti-thyroid antibodies; two against parietal cells; one for anti-
amphiphysin; one for rheumatologic antibodies (Anti-Sjo¨gren’s-
syndrome-related antigen A and anti-nuclear antibody);23 one for
non-specific immunoglobulin (Ig)M against tick-borne meningoence-
phalitis; and one for anti-N-methyl-D-aspartate receptor antibodies.
Four of these seven patients had two or more detectable autoantibodies
in serum.23–26 Only the patient with antibodies against tick-borne
meningoencephalitis had them in both serum and CSF.6 Testing
for oligoclonal bands (OCBs) was reported in 17 patients (24.6%),
and they were detected in nine. Electromyography (EMG) findings
were reported in 36 patients (52.2%), with findings consistent with SPS
in 26.
As shown in Table 2, the two most commonly used treatments were
benzodiazepines and intravenous immunoglobulin, which were used in
45/69 cases (65.2%). Baclofen followed as the third most commonly used
agent (26/69 cases, or 37.7%). Fifty-eight patients (84.1%) received either
intravenous immunoglobulins, plasmapheresis, rituximab, steroids, or a
steroid-sparing immunosuppressant. In terms of outcomes, 54 reported
improvement (78.3%), nine (13%) remained stable, and three (4.3%)
either worsened or died (one of these had PERM; the other two had SPS,
one of which was also had concomitant corticobasal syndrome).27–29
Eighteen of the 54 (33.3%) patients who improved experienced at least
one relapse at some point in the course of their disease.
Paraneoplastic SPS-spectrum cases (Table 3)
There were 19 paraneoplastic SPS-spectrum cases. Thirteen were
females. The median age at presentation was 59 (range 21–81) years.
Eleven had SPS, four of whom also had other neurologic disorders (two
with limbic encephalitis; one with ataxia; and one with opsoclonus–
myoclonus). Three cases were consistent with SLS and two with PERM.
One had West Nile encephalitis with positive anti-GAD antibodies;
another had a ‘‘paraneoplastic centrally mediated disorder with central
planning’’ but had no detectable antibody; and the remaining case had
isolated opsoclonus–myoclonus with serum anti-GAD antibodies.30,31
Ten cases documented the time between symptom onset and
presentation with a median of 3 months and ranging from weeks up
to 13 years. Fifteen patients described gait difficulties, 11 reported pain,
12 had cramps or spasms, and 13 had limb stiffness.
All cases had a documented malignancy, the most common being
breast cancer (eight cases). Malignancies of the following organs were also
reported: thymus (three cases); colon (two); and lung (two). The remaining
four cases had either Hodgkin’s lymphoma, leukemia, mesothelioma, or
melanoma. In terms of comorbidities, only one had pre-existent diabetes
(another four were documented not to be diabetic) and screening for
autoimmunity was documented in only one case (and not detected).
The antibody profile was varied. Seventeen cases were tested for
anti-GAD antibodies, of which eight were positive. Anti-GlyR
antibodies were tested in two cases, one was positive. Thirteen cases
were tested for other antibodies, and the following were identified: four
were seropositive for anti-amphiphysin antibodies (two cases had
antibodies also in CSF) and one was positive for anti-Ri antibodies in
both serum and CSF. No antibodies were detected in five. Oligoclonal
bands were tested in eight, and four were positive. Seven had EMGs,
with six having features consistent with SPS.
Benzodiazepines and cancer treatment (chemo- or radiotherapy)
were employed in 13 cases. Nine cases underwent oncologic surgery,
and 16 patients received some kind of cancer treatment, including
chemotherapy, radiotherapy, and/or oncologic surgery. Despite all of
these patients having a malignancy, 16 improved neurologically (one of
them deteriorated eventually). Two remained stable and two others
worsened, one of whom succumbed to mesothelioma after having
previously improved from a neurologic standpoint. Four of the 16
patients who improved experienced at least one relapse.
Cryptogenic SPS-spectrum cases (Table 4)
There were 13 cryptogenic cases. Four were female, nine were male.
The ages ranged from 7 to 75 years, with a median age of 44 years. Of
these 13, 11 had SPS, including a patient who initially presented with
SLS.32 Among the two remaining cases, one had SLS and the other had
PERM. Data for 11/13 patients regarding the time between symptom
onset and presentation ranged from less than 1 month to 14 years, with the
median being 9 months. All of the cases had either cramps or spasms, and
nine had limb stiffness. Other common symptoms were pain (reported in
11 cases) and gait difficulties (nine). Only one case had concomitant
autoimmunity (thyroid disease and vitiligo),33 and absence of concomitant
autoimmunity was only reported in another case.14 Eleven of 13 reported
testing for commonly associated antibodies, and all of them were negative
for either anti-GAD or anti-GlyR antibodies. Of these 11, one reported
positive OCBs34 while another documented absence of this finding (the
patient with PERM).35 EMG findings consistent with SPS were reported
in seven. The most commonly used medication was a benzodiazepine
(12 cases). Treatment outcomes in this cohort were overwhelmingly
positive. Twelve reported improvement and the thirteenth stabilized, but
there was no mention of worsening or death. Among the 12 who
improved, only the PERM case relapsed.35
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Case series of patients with anti-GAD antibodies and cerebellar
ataxia (Table 5)
Arin˜o et al.21 described 34 cases of cerebellar ataxia with anti-GAD
antibodies. Data are consolidated for the cohort, as individual details for
each of these 34 are not available. Twenty-eight of the 34 patients were
female. Gait difficulty was the most common symptom in this cohort
(91.2%). Concomitant autoimmunity was reported for well over half, with
thyroid disease being the most prevalent (52.9%). Cancer was detected in
four cases (11.8%). Different immunosuppressant agents were the
treatment of choice, and outcomes varied considerably with a subacute
course and early medical treatment being good prognostic indicators.
Discussion
Segregation of SPS-spectrum cases based on likely etiology allowed
detecting similarities and differences between categories. It also
allowed identifying themes within each group. Perhaps the most
evident observation is the phenotypical variability present within each
group. The data demonstrate that SPS, SLS, or PERM can all be
found in autoimmune, paraneoplastic, or cryptogenic SPS-spectrum
disease. This lack of specificity hinders the examiner’s ability to predict
an etiology based solely on clinical features.
By definition, the presence of anti-GAD antibodies includes a
condition within the SPS spectrum. However, these antibodies do not
differentiate between paraneoplastic and autoimmune causes as they
are present in both. In this review over 80% of autoimmune SPS-
spectrum cases were positive for anti-GAD antibodies, but close to 50%
of paraneoplastic cases were also seropositive. Additional antibodies
(anti-amphiphysin antibodies) can increase specificity, particularly
when multiple antibodies are present, in which case anti-amphiphysin
antibody seropositivity should encourage an investigation for an
underlying malignancy. The presence of multiple antibodies further
supports the notion that anti-GAD antibodies are not the sole
pathogenic cause but that the GABA synthesis apparatus along with
its associated pathways are disrupted. It also suggests that it is important
to obtain CSF in these patients with multiple antibodies as some are
predominantly found in the CNS, such as GAD67,21 particularly when
clinical findings or preliminary serum tests are inconclusive.
Anti-GlyR antibodies were the second-most commonly observed
after anti-GAD antibodies. In this review, 11 autoimmune SPS-
spectrum cases had anti-GlyR antibodies in serum (15.9%), nine had
them in CSF (13%), seven had antibodies in both CSF and serum
(10.1%), and two only in CSF but not in serum (2.9%). The phenotypes
included PERM, three with SPS, one with stiff trunk syndrome, and
one with behavioral changes and epilepsy. Interestingly, among the
patients who had antibodies in both CSF and serum, one had
prodromal reduction in taste,25 one had prodromal pruritus,36 and a
last one had both.37 All of them were eventually diagnosed with PERM.
We find this observation clinically relevant, since changes in taste and
pruritus may be specific enough to predict a diagnosis of PERM in the
right clinical context. This could ultimately translate into prompt
initiation of immunosuppressive treatment. In contrast to autoimmune
cases, anti-GlyR antibodies were only found in one paraneoplastic case:
a case of SLS in the setting of leukemia.38 Thus, the presence of anti-
GlyR antibodies despite the clinical phenotypic variation may strongly
suggest a more autoimmune pathology rather than a paraneoplastic
variation, unlike anti-GAD antibodies, which are present in both.
Paraneoplastic SPS-spectrum cases too present with a myriad of different
phenotypes. Because of this, it may be prudent to screen for malignancy in
all patients with symptoms consistent with the SPS-spectrum, although,
admittedly, it may not be cost-effective. Thus, we recommend a step-wise
approach, first with brain and spine MRI, routine blood work, including
complete blood count, comprehensive metabolic panel, and B12 level,
EMG/nerve conduction studies, and lumbar puncture assessing for
autoimmune and infectious causes before a malignancy screen. If this
preliminary work-up and subsequent serum and CSF paraneoplastic
antibody panels are negative, whole-body positron emission tomography is
recommended to assess for occult malignancy. The possible scenario in
which this intervention may be most cost-effective is in patients with
opsoclonus–myoclonus. We identified the opsoclonus–myoclonus pheno-
type to be specific for paraneoplastic cases, as seen in two out of 19
paraneoplastic cases, as opposed to none of the 69 autoimmune or the 13
cryptogenic cases. However, if serum anti-amphiphysin antibodies are
detected, a specific search for breast malignancy should be undertaken as
previous reports19,39 and our current analysis show a high likelihood of
associated breast cancer.
Among ancillary testing, EMG is particularly useful. Although not
consistently reported, EMG was positive in 72.2% of all EMG-tested
autoimmune cases, 85.7% of paraneoplastic cases, and 87.5% of the
cryptogenic EMG-tested cases. Given this apparent high probability of
a confirmatory finding, we advocate for routine EMG testing in all
suspected SPS-spectrum cases featuring rigidity, dystonic posturing, or
cramping. However, there were no specific EMG findings to
differentiate among the subgroups. One important consideration
based on both our literature review and experience is that the
pathognomonic EMG findings may take some time to develop.33
Thus, in cases where an initial EMG is negative, a repeat EMG should
be performed in at least 3 months’ time if the clinical suspicion is high.
Thus, the constellation of commonalities within groups is most
helpful when attempting to identify the cause of a SPS-spectrum
condition, rather than relying solely on clinical features or a single
antibody. Thus, the presence of a concomitant autoimmune condition,
anti-GAD antibodies, and symptoms of a SPS-spectrum disorder
suggests an autoimmune pathomechanism. However, anti-amphiphy-
sin antibodies in the presence of these symptoms and a malignancy
suggest a paraneoplastic etiology. Although this may not be absolute, it
can provide a guide to quickly diagnose and appropriately treat these
patients. For example, in patients with paraneoplastic disease,
treatment of the underlying malignancy with chemo/radiotherapy
and oncologic surgery should be the focus of care.
Whereas we are confident of our autoimmune and paraneoplastic
classifications, we have reservations with the cryptogenic category. We
believe that this category can potentially include autoimmune cases for
which a known antibody is either present in titers that evade detection, or
are positive for antibodies that are yet to be recognized. The response to
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immunosuppression (plasmapheresis, steroids) in five out of 13 cases argues
in favor of this theory. Of note, these patients also received other
interventions, and it is impossible to ascertain which agent(s) was responsible
for the symptomatic response. In addition, the presence of a microscopic
malignancy in some of these cases cannot be completely excluded, and
patients with cryptogenic SPS-spectrum disease may eventually declare
themselves as paraneoplastic, granted a sufficient follow-up period is
allowed. Finally, the absence of both antibodies and EMG evidence to
support a diagnosis of SPS-spectrum disease opens the possibility for
cramping syndromes or other conditions featuring rigidity to be
misclassified within the SPS spectrum. The differential diagnosis of SPS
is vast and includes myelopathy, myopathy, Isaac’s syndrome, Parkinson’s
disease and atypical parkinsonian syndromes, primary lateral sclerosis,
ankylosing spondylitis, neuroleptic malignant syndrome, serotonin syn-
drome, hereditary or tropical spastic paraparesis, spinal interneuronitis with
rigidity, dystonia, neuromyotonia, and tetanus.6,37 With this differential in
mind, in seronegative patients with inconclusive EMGs, a comprehensive
work-up can include a complete blood cell count, a comprehensive
metabolic panel, thyroid function tests, creatine kinase, erythrocyte
sedimentation rate, C-reactive protein, serum B12 level, human T-cell
lymphotropic virus-1, rheumatoid factor, antinuclear antibody, computed
tomography (CT) chest screening for a mediastinal mass, CT abdomen and
pelvis, MRI brain, and CSF analysis including oligoclonal bands and IgG
index.15
With these caveats in mind, the great majority of cryptogenic cases
were diagnosed with SPS. Interestingly, unlike autoimmune and
paraneoplastic cases, the majority of cryptogenic cases were male. This
may be an indication of a different pathophysiology within this group,
but the significance of this finding is unclear. The majority of cryptogenic
cases in this review reported symptomatic improvement. However, some
of the success was with novel interventions for SPS (including spinal cord
stimulation,32 physical therapy,40 dantrolene,41 intrathecal baclofen,42
and cannabis43). We find this likely constitutes a reporting bias, since it is
possible that cases in which novel interventions were unsuccessful may
not have been published. Thus, we wonder whether the prognosis of
these patients is as favorable as the data in this review suggested.
There are certain limitations to consider regarding our data. To
start, the prevalence estimates of SPS, PERM, and other variants
among the three subdivisions were based on the original published
descriptions. It was difficult for us to ensure that the specific criteria
established by Dalakas were met, as clinical descriptions were often
incomplete. We are thus relying on the original author’s clinical
judgment in diagnosing these patients with the said conditions. It is
possible that those diagnosed with classical SPS may in fact have been
a variant and vice versa. In addition, both the paraneoplastic and the
cryptogenic groups had fewer than 20 cases each, making inferences
from these groups difficult to generalize. Furthermore, many of the
cases reported describe treatment successes, and it is possible that this
overestimates the response rates of patients with these conditions. In
addition, it is impossible to demonstrate the complete absence of
cancer in all of the autoimmune cases, just as it is impossible to
guarantee that an autoimmune (and not a paraneoplastic) etiology is
not responsible for SPS symptoms in some of the paraneoplastic cases.
Finally, it is unclear whether the data acquired would vary significantly
should our search be expanded to include cases in other languages, or
cases reported before 2010.
Overall, this review supports the idea that, unlike the original
descriptions, SPS encompasses a spectrum of diseases related by their
clinical symptoms, the presence of autoantibodies, EMG findings, and
its response to immunomodulation and muscle relaxants. Despite these
commonalities, different causative mechanisms are likely among the
disorders, and their classification based on likely etiology can guide
treatment and provide useful prognostic information. As new asso-
ciated antibodies and associated clinical features are discovered, it is
possible that the spectrum will continue to expand. Ultimately, a high
degree of clinical suspicion is necessary to initiate the work-up and
select appropriate treatment that can be initiated in a timely fashion.
Future directions in the management of these conditions may emerge
as we better understand the role, if any, that these antibodies play in
the emergence of symptoms. This could lead to the development of
targeted therapies that minimize systemic side effects.
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